MAIA Biotechnology, Inc. - Form 8-K Summary
Business Context and Reporting Period
MAIA Biotechnology, Inc. (MAIA), a Delaware corporation and emerging growth company, filed this Current Report on Form 8-K on February 25, 2025, regarding events occurring on February 24, 2025. The company is focused on clinical development, specifically the THIO-101 program.
Key Financial Metrics and Transaction Details
This filing reports a private placement financing event rather than periodic financial results. Key transaction metrics include:
- Total Gross Proceeds: Approximately $1.43 million.
- Investor Component: 894,300 shares of Common Stock and warrants to purchase 894,300 shares at $1.50 per share, totaling approximately $1.34 million.
- Director Component: 58,333 shares of Common Stock and warrants to purchase 58,333 shares at $1.50 per share, totaling approximately $87,500.
- Warrant Terms: Exercise price of $1.85 per share; exercisable one year after issuance; six-year term.
- Closing Date: Expected on February 26, 2025.
The filing does not provide current revenue, profit, cash flow, or debt figures.
Material Changes and Use of Proceeds
The primary material change is the entry into a Securities Purchase Agreement for a private placement. The company intends to use the net proceeds to:
- Fund the starting costs for Part C of the Phase 2 THIO-101 clinical trial.
- Provide working capital.
Guidance, Risks, and Unusual Items
Management Commentary: The Board determined that allowing directors to participate in the private placement aligns their interests with stockholders and recognizes their past and future services.
Risks and Contingencies:
- Unregistered Securities: The shares and warrants are issued as restricted securities under Rule 144 and have not been registered under the Securities Act of 1933.
- Closing Conditions: The transaction is subject to the satisfaction of customary closing conditions.
- Registration Rights: The securities sold do not contain any registration rights.
Investor Verification Checklist
- Verify the actual closing of the transaction on or around February 26, 2025.
- Confirm the final net proceeds after deducting offering expenses.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) and Warrant forms (Exhibits 4.1 and 4.2) for specific adjustment provisions and covenants.
- Monitor subsequent filings for the commencement of the Phase 2 THIO-101 Part C clinical trial.